BioVie Presents New Biomarker Data from the ADDRESS-LC Trial of Bezisterim in Long COVID
BioVie Inc. announced new biomarker findings from its Phase 2 ADDRESS-LC trial of bezisterim, which were presented at the 2026 RECOVER–Treating Long COVID (RECOVER-TLC) Hybrid Workshop.